Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group

A. Ryska, R. Buiga, A. Fakirova, I. Kern, W. Olszewski, L. Plank, S. Seiwerth, E. Toth, E. Zivka, C. Thallinger, C. Zielinski, L. Brcic,

. 2018 ; 23 (12) : e152-e158. [pub] 20180803

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045328

This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. IMPLICATIONS FOR PRACTICE: This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045328
003      
CZ-PrNML
005      
20200120102315.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1634/theoncologist.2018-0008 $2 doi
035    __
$a (PubMed)30076278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic.
245    10
$a Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group / $c A. Ryska, R. Buiga, A. Fakirova, I. Kern, W. Olszewski, L. Plank, S. Seiwerth, E. Toth, E. Zivka, C. Thallinger, C. Zielinski, L. Brcic,
520    9_
$a This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. IMPLICATIONS FOR PRACTICE: This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.
650    _2
$a nemalobuněčný karcinom plic $x epidemiologie $x patologie $x terapie $7 D002289
650    _2
$a výdaje na zdravotnictví $x normy $7 D005102
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x epidemiologie $x patologie $x terapie $7 D008175
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Buiga, Rares $u "Prof. Dr. Ion Chiricuta" Institute of Oncology, Cluj-Napoca, Romania.
700    1_
$a Fakirova, Albena $u Department of Pathology, Military Medical Academy, Sofia, Bulgaria.
700    1_
$a Kern, Izidor $u University Clinic Golnik, Golnik, Slovenia.
700    1_
$a Olszewski, Włodzimierz $u Department of Pathology Institute of Oncology, Warsaw, Poland.
700    1_
$a Plank, Lukas $u Department of Pathology, Comenius University Jessenius Medical Faculty University Hospital, Martin, Slovakia.
700    1_
$a Seiwerth, Sven $u Institute of Pathology, University of Zagreb School of Medicine and Clinical Hospital Center, Zagreb, Croatia.
700    1_
$a Toth, Erika $u National Institute of Oncology, Budapest, Hungary.
700    1_
$a Zivka, Eri $u Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
700    1_
$a Thallinger, Christiane $u Department of Medicine I, Division of Oncology, Medical University of Vienna, General Hospital, Vienna, Austria. Central European Cooperative Oncology Group (CECOG), Vienna, Austria.
700    1_
$a Zielinski, Christoph $u Comprehensive Cancer Center and Vienna Cancer Center, Medical University of Vienna, General Hospital, Vienna, Austria. Central European Cooperative Oncology Group (CECOG), Vienna, Austria.
700    1_
$a Brcic, Luka $u Institute of Pathology, Medical University of Graz, Graz, Austria luka.brcic@medunigraz.at.
773    0_
$w MED00005061 $t The oncologist $x 1549-490X $g Roč. 23, č. 12 (2018), s. e152-e158
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30076278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200120102651 $b ABA008
999    __
$a ok $b bmc $g 1483597 $s 1084001
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 23 $c 12 $d e152-e158 $e 20180803 $i 1549-490X $m The oncologist $n Oncologist $x MED00005061
LZP    __
$a Pubmed-20200109
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace